November 16, 2025 · Form 4 insider transaction
Niklason Laura E bought 311,100 shares of Humacyte, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.